Themis Medicare Limited
Momentum (87/100) does the heavy lifting; quality (27/100) is the drag.
Fair valueThemis Medicare Limited earns a Hold from StocksWizard, with a blended score of 54/100. We put fair value near ₹207.53; at ₹128.25 that leaves roughly 62% upside, so the stock screens undervalued by 62%. The price is about 10% below its 52-week high of ₹142.46 and 94% above the low of ₹66.07. Financial health scores 84/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 1/9. It clears 7 of 12 investability checks, with durability 27, valuation 36 and momentum 87 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹166.02. Low-confidence estimate — limited data.
1-year price
EOD · 2026-09-1452-week range
-9.97% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold54Piotroski F-score 1/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 0.3%
- Pass: Low debt (D/E < 0.5): 0.25x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 7%
- No data: Earnings growing
- Fail: Net margin ≥ 10%: 0.3%
- Pass: Current ratio > 1.5: 1.83
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.36
- Fail: Piotroski ≥ 7: 1/9
Shareholding
- Promoter74.9%
- Institutions0.0%
- Public & other25.1%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 4.36.
Opportunities
- Trades ~62% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (0.3%).
- Weak Piotroski score (1/9).
About Themis Medicare Limited
Themis Medicare Limited manufactures and sells pharmaceutical products across India and international markets. The company produces active pharmaceutical ingredients and formulations for therapeutic areas including anti-tuberculosis, analgesic, anti-inflammatory, antispasmodic, anesthetic, antacid, antifungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, and anti-allergic applications.
Themis Medicare Limited — frequently asked questions
Is Themis Medicare Limited a buy, hold or sell?
StocksWizard currently rates Themis Medicare Limited (THEMISMED) a Hold, based on a blended score of 54/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Themis Medicare Limited's fair value?
Our blended DCF and relative-valuation model estimates Themis Medicare Limited's fair value at about ₹207.53, versus a current price of ₹128.25 — roughly 62% upside. On that basis the stock looks undervalued by 62%.
Is Themis Medicare Limited financially healthy?
Themis Medicare Limited scores 84/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 1/9.
How has Themis Medicare Limited's share price performed?
Themis Medicare Limited is up 25% over three months, and last traded at ₹128.25. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.